EnteroBiotix Limited (EnteroBiotix), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, announced that results from its IMPuLCE phase 1b trial evaluating EBX-102, the company’s next-generation full-spectrum microbiome product, in patients with liver cirrhosis will be shared as an oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place in Amsterdam, the Netherlands from 7-10 May 2025.
Presentation Title: A multicentre randomised double-blind placebo-controlled phase 1b clinical trial evaluating the safety and mechanism of action of EBX-102, an oral pooled intestinal microbiota product, in liver cirrhosis: the IMPuLCE trial -- Presenter: Professor Ewan Forrest, Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK -- Session: Cirrhosis I: Cirrhosis & Complications -- Session date and Time: 09 May 2025, 08:45-09:00 CEST --Presentation ID: OS-036 -- Location: Benhamou Room.
EBX-102 is a next-generation, full-spectrum microbiome therapeutic composed of a high-diversity consortium of gut-derived microbes. Manufactured using the company’s proprietary AMPLA technology, EBX-102 has a robust stability profile and is formulated as an off-white, odourless powder encapsulated into oral capsules. It is designed to deliver rapid, well-tolerated, and effective symptom relief for diseases associated with gut microbiome dysfunction, including liver cirrhosis and complications thereof, such as hepatic encephalopathy (HE).
EnteroBiotix is a clinical-stage biotechnology company developing microbiome-based therapeutics for irritable bowel syndrome (IBS) and other gastrointestinal and hepatic indications. Using its proprietary platform technology, EnteroBiotix creates next-generation therapies with differentiated characteristics designed to restore and enhance gut microbiome function.
